Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396226 | 0.88 | ADORA2A (0.43) | ADORA2AADORA2BTTRALDH1A1MEN1 | |
| SCHEMBL3273312 | 0.79 | KMO (0.42) | TTRALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30224316 | 0.79 | KMO (0.42) | TTRALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL17476800 | 0.78 | ADORA3 (0.48) | ADORA2AADORA2BCNR1ADORA1 | |
| SCHEMBL31047274 | 0.78 | ADORA2A (0.49) | ADORA2AMEN1KMT2AACMSDADORA1 | |
| SCHEMBL16151213 | 0.78 | ADORA2A (0.49) | ADORA2AMEN1KMT2AACMSDADORA1 | |
| SCHEMBL14926554 | 0.76 | TTR (0.46) | TTRALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL17436348 | 0.76 | FEN1 (0.46) | TTRALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL25693851 | 0.76 | ADORA2A (0.49) | ADORA2AADORA2BTTRALDH1A1MEN1 | |
| SCHEMBL24820600 | 0.75 | EIF4E (0.48) | TTRALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985005-A1 | FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR | Medshine Discovery Inc. (CN) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249096-A1 | FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR | 南京明德新药研发有限公司 | 2020-12-17 | — | — | WO | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| CN-105283443-B | Hete rocyclic derivatives and application thereof | 株式会社C&C新药研究所 | 2018-08-17 | — | — | CN | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| EP-2981533-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2017-12-06 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2981533-A1 | PROTEIN KINASE INHIBITORS | Orion Corporation (FI) | 2016-02-10 | — | — | EP | disclosed |
| US-20160031855-A1 | PROTEIN KINASE INHIBITORS | ORION CORPORATION (FI) | 2016-02-04 | — | — | US | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014162039-A1 | PROTEIN KINASE INHIBITORS | ORION CORPORATION (FI) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | ADORA2A 3818/4885ADORA2B 4325/4885TTR 1936/4885 |
| US-20160031855-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ADORA2A 3300/4885ADORA2B 2242/4885TTR 4661/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | ADORA2A 3818/4885ADORA2B 4325/4885TTR 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.